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diagnostic tool for early detection of breast 
cancer
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Abstract 
There has been tremendous progress in detection of breast cancer in postmenopausal women, resulting in two‑thirds 
of women surviving more than 20 years after treatment. However, breast cancer remains the leading cause of cancer‑
related deaths in premenopausal women. Breast cancer is increasing in younger women due to changes in life‑style 
as well as those at high risk as carriers of mutations in high‑penetrance genes. Premenopausal women with breast 
cancer are more likely to be diagnosed with aggressive tumours and therefore have a lower survival rate. Mammogra‑
phy plays an important role in detecting breast cancer in postmenopausal women, but is considerably less sensitive 
in younger women. Imaging techniques, such as contrast‑enhanced MRI improve sensitivity, but as with all imaging 
approaches, cannot differentiate between benign and malignant growths. Hence, current well‑established detection 
methods are falling short of providing adequate safety, convenience, sensitivity and specificity for premenopausal 
women on a global level, necessitating the exploration of new methods. In order to detect and prevent the disease 
in high risk women as early as possible, methods that require more frequent monitoring need to be developed. The 
emergence of “omics” strategies over the last 20 years, enabling the characterisation and understanding of breast can‑
cer at the molecular level, are providing the potential for long term, longitudinal monitoring of the disease. Tissue and 
serum biomarkers for breast cancer stratification, diagnosis and predictive outcome have emerged, but have not suc‑
cessfully translated into clinical screening for early detection of the disease. The use of breast‑specific liquid biopsies, 
such as nipple aspirate fluid (NAF), a natural secretion produced by breast epithelial cells, can be collected non‑inva‑
sively for biomarker profiling. As we move towards an age of active surveillance, home‑based liquid biopsy collection 
kits are increasingly being applied and these could provide a paradigm shift where NAF biomarker profiling is used for 
routine breast health monitoring. The current status of established and newly emerging imaging techniques for early 
detection of breast cancer and the potential for alternative biomarker screening of liquid biopsies, particularly those 
applied to high‑risk, premenopausal women, will be reviewed.
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Background
Breast cancer is a global health problem affecting women, 
and to a lesser extent men, and constituted 25% of all 
cancers in 2012, with 883,000 cases each year in less 
developed and 794,000 cases in more developed regions 
of the world [1]. There were 458,000 breast cancer-related 
deaths worldwide (269,000 in developing and 189,500 in 
developed countries) in 2008 [2]. Furthermore, it is the 
leading cause of death in the world among women aged 
40–59  years, and in premenopausal women, incidence 
and mortality has increased in South America, Central 
America and Africa [3, 4]. Analysis of the SEER (1988–
2003 Surveillance, Epidemiology and End Results) Pro-
gram data, comparing women less than 40 years old with 
those more than 40  years old, indicated that although 
they only constituted 6.4% of the study, they were more 
likely to die from breast cancer [5]. Limited breast health 
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awareness and access to screening has a significant 
impact on the ability of health services to diagnose and 
treat the disease at a sufficiently early stage, and in many 
cases, by the time the patient presents at clinic, the can-
cers have already become aggressive. This problem is not 
unique to less developed countries as deaths also reached 
an all-time high during 2010 in the UK for women under 
50 years old. The risks associated with breast cancer are 
well established and include genetic predisposition [6, 
7], reproductive factors (menarche, parity, lactation, 
menopause) [8–10], environment (chemical exposures, 
drugs, infectious agents) [11, 12], demographic factors 
(age, race, sex, socio-economic status, geographic loca-
tion) [13], systemic factors (epigenetics) [14] and lifestyle 
(smoking, alcohol use, diet, obesity, exercise) [15].
The major risk factor is age and the majority of breast 
cancer cases occur in women after menopause. However, 
the correlation of risk with reproductive, environmental 
and lifestyle parameters, strongly indicate the origins of 
many breast cancers are concealed by a prolonged period 
of dormancy that only manifest in later life [16]. Lifestyle 
parameters are unique among these factors, since they 
can be modified and consequently fall within the scope 
of the individual to proactively reduce these risks by tak-
ing preventative measures, whereas genetic, reproduc-
tive, environmental and demographic factors are beyond 
the control of most individuals. Women at highest risk, 
accounting for 5–10% of cases, are those who inherit 
gene mutations, and have 10- to 30-fold higher chance of 
developing breast cancer during their lifetime compared 
to the general population. Genetic predisposition can be 
identified initially through investigation of family history 
of the disease and confirmed by screening for predic-
tive mutations associated with specific high-penetrance 
genes, such as the BRCA1, BRCA2, TP53 and PTEN 
genes [6].
The emergence of genomic technologies in the last 
20  years has had a major impact on understanding dis-
ease stratification in breast cancer, which is not only 
providing insights on how the disease progresses, but 
clinical direction in targeted treatment and prediction of 
outcome. There are currently 5 main phenotypes, Lumi-
nal A, Luminal B, Her2, basal-like and Claudin-low, but 
further stratification can be anticipated [17]. At the sim-
plest level, each phenotype is defined by expression or 
absence of three cell surface proteins, estrogen receptor 
(ER), progesterone receptor (PR) and human epidermal 
growth factor receptor (HER2). These phenotypes also 
correlate with normal mammary cellular development 
[18]. Claudin-low and Basal-like types, originating from 
breast stem and progenitor cells, respectively, constitute 
the majority of triple negative breast cancers (TNBC), 
which have a particularly poor prognosis, no targeted 
treatment, high chance of re-occurrence and poor overall 
survival. TNBC is also strongly associated with BRCA1/
BRCA2 induced cancer [19] and with obesity in premen-
opausal women [20].
Because of extensive epidemiological and etiological 
studies, it is becoming easier to identify those women 
who are at highest risk of breast cancer. Unfortunately, 
none of these measures can predict when breast cancer 
will occur. Regular screening for the appearance of breast 
cancer, which is recommended for women reaching 
menopause, is even more critical in high risk women dur-
ing their reproductive years. There are various screen-
ing modalities, each with advantages and disadvantages 
(Table  1), making them sub-optimal for more frequent 
monitoring as required by this group. As a consequence, 
the major means of preventative intervention for these 
women can be extreme, involving elective pre-sympto-
matic surgery to remove both breasts. Therefore, new 
and more sensitive approaches are required to detect the 
earliest stages of the disease, which will enable less dras-
tic means of intervention. Initially, we review the vari-
ous established screening methods, to understand their 
limitations.
Breast cancer detection
Self‑examination
Self-examination encourages women to be involved in 
active surveillance of their own breast health, increas-
ing awareness of changes, both natural and abnormal. It 
provides an effective way for early detection of up to 50% 
tumours and improves discovery of other breast-related 
diseases without involving specialist equipment or pro-
fessional health care assistance [21]. However, the preva-
lence of breast self-examination is still low, particularly in 
educationally-deprived and developing countries [22].
Mammography
Mammography is by far the most common approach for 
screening breast cancer. In Europe, women aged 50–70 
are invited for breast screening every 2–3  years, while 
in US annual mammograms are recommended from 50 
to 74 years equating to nearly 39 million images in 2014. 
Women who have an increased risk of developing breast 
cancer, but are too young to join national screening pro-
grams, are offered annual screening using mammography 
and magnetic resonance imaging (MRI) based on a risk–
benefit decision. Sensitivity of mammography can vary 
from almost 100–40% dependent on tissue composition 
[23, 24], and positive association for prediction of disease 
is only 50%. False-positive rates in breast cancer screen-
ing are a significant limitation, as high call-back rates and 
unnecessary biopsies result in increased cost, radiation 
exposure, and patient anxiety during re-screening [25, 
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26]. Over a period of 20 years, based on 7 trials of more 
than 600,000 women, screening was shown to reduce 
breast cancer mortality by 15% however over-diagnosis 
was estimated at 29% [27, 28]. In particular, mammog-
raphy is approximately 10–15% less sensitive in women 
under 50 than in postmenopausal women [29]. Women 
in their 40s screened within the UK Age Trial had a 5% 
risk of a false-positive result at their first screen [30] and 
a random clinical trial of 161,000 women showed that 
women aged 39 onwards did not significantly reduce 
their risk of dying from breast cancer within 5–15 years 
[31].
The continuing development of mammography, includ-
ing digitisation with improved resolution (full field digi-
tal mammography), has strengthened its position as the 
Gold standard for screening but still requires the pres-
ence of a substantial mass in the breast for a diagnosis 
[32, 33]. Many breast tumours may have already metas-
tasised before detection by mammography. Equally, a 
mammogram cannot always distinguish between benign 
micro-calcifications associated with low risk DCIS 
(therefore may not require surgical treatment) and higher 
risk DCIS that will progress to a malignant invasive 
tumour [34]. Even when supported by histopathological 
screening of core biopsies, there has been a tendency to 
over-diagnose and over-treat DCIS cases [35]. Conse-
quentially, some women receive a false-positive diagnosis 
resulting in unnecessary surgery to remove the lump or 
whole breast. Radiation exposure has also been shown to 
contribute to increased incidence of breast cancer, par-
ticularly in high risk populations, resulting in heart dis-
ease induced by breast or cell wall radiotherapy [23].
One of the challenges for imaging methods is breast 
tissue density, which is higher in younger women, mak-
ing their mammograms harder to interpret, whereas 
postmenopausal women with extensive fatty breast tis-
sue or ductal atrophy are more likely to have an accurate 
diagnosis [36]. Breast density is strongly associated with 
tissue composition (collagen, epithelial cell and non-
epithelial cell content, glandular area), genetic influences 
and hormonal regulation (prolactin, IGF-1). Further-
more, mammographic density is positively associated 
with alcohol consumption, smoking in post-menopausal 
women and with breast cancer [36, 37]. It is possible to 
quantitatively measure breast density using established 
and specialised imaging modalities in combination with 
bespoke algorithms [38], however this strategy has not 
been widely accepted.
Other imaging techniques
Digital breast tomosynthesis (DBT) is a relatively new 
screening approach, which uses an X-ray beam in an arc 
around the breast to provide a 3D reconstruction of the 
tissue. In a comparison of DBT with digital mammog-
raphy for 2666 breast lesions, the former had improved 
performance (sensitivity and specificity of 90 and 79%, 
respectively) compared to the latter (89 and 72%, respec-
tively) [39], but was also subject to the same limitations 
incurred by breast density. There are fewer recalls with 
DBT compared to digital mammography, particularly in 
younger women, and although approved by the Food and 
Drug Administration for breast screening, it is not widely 
available [40]. Ultrasonography, using high-resolution 
linear transducers, is readily accessible, similar in cost to 
Table 1 A semi-quantitative comparison of liquid biopsies that have been used for breast cancer biomarker discovery
(+) Accessibility enhanced by oxytocin nasal spray
*Comparison of healthy and disease sample pairs provides an internal reference
Liquid biopsy Volume Accessibility Discomfort Reference 
sample*
Sample 
preparation
Biomarker 
concentration
Patient led 
collection
Convention
Plasma ++ +++ +++ X ++++ ++ X +++++
Urine +++++ +++++ + X +++ + √ ++++
Saliva +++ +++++ + X ++ + √ +++
Ductal lavage + + ++++ √ + +++++ X +
Random 
Periareolar 
Fine Needle 
Aspiration
+ + +++++ √ ++ +++++ X +
Nipple Aspirate 
Fluid
+ +++(+) ++ √ + +++++ √ ++
+ Small Invasive No discomfort/
no distress
Extensive 
processing 
required
Low Infrequent use 
for biomarkers
+++++ Large Easily available Painful/stressful Limited pro‑
cess required
High Frequent use for 
biomarkers
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mammography and moderately improves cancer detec-
tion, but has lower specificity, lower positive predictive 
value and was similarly obfuscated by tissue density [41].
Contrast-enhanced MRI, by comparison is not limited 
by breast density, nor does it use ionising radiation. In a 
review of 11 studies comparing MRI with digital mam-
mography, the former achieved 94% sensitivity, but iden-
tified few cases of cancer in addition to those discovered 
by digital mammography alone [42]. Furthermore, MRI 
exhibited relatively low specificity, was time consuming, 
had limited accessibility and high cost to run. Positron 
Emission Tomography with computer tomography (PET-
CT) uses gamma-radiated emitting fluorine-18 fluorode-
oxyglucose (FDG), a glucose analogue, injected into arm 
veins to accumulate in areas of high metabolic activity, 
such as tumours, and is then detected using a PET-CT 
x-ray scanner [43]. Sensitivity of PET-CT ranged from 
71 to 90%, which was improved further when combined 
with mammography, but results were affected by breast 
size [44]. However, PET-CT is more often used to assist 
surgery to remove diseased tissue rather than as a front 
line routine screen for initial detection of breast cancer. 
Wave elastography uses ultrasound or MRI techniques 
to measure tissue stiffness, which is positively associ-
ated with a tumour mass compared to normal tissue. The 
application of shear wave elastography, which uses the 
force of acoustic radiation produced by an ultrasound 
beam, demonstrated improved sensitivity and specificity 
[45]. Electrical impedance scanning is another modality 
under development for breast cancer detection especially 
in young women with dense breasts, which is based on 
lower electrical impedance in malignant tumours com-
pared to the surrounding normal tissue [46]. Recent 
technological advances have facilitated dynamic thermal 
analysis of the breast by recording of circadian rhythm 
variations and analysing the recorded data using highly 
sophisticated statistical algorithms, but this approach 
currently suffers from high false positive rates [47]. 
Although showing great promise, none of these inno-
vative imaging approaches are in a position to replace 
mammography as the mainstream approach to routinely 
detect breast cancer and most importantly cannot differ-
entiate between benign and malignant growths.
Biomarkers
There have been extensive studies to identify breast can-
cer biomarkers, but with varying degrees of success. 
Genomics has already stratified the disease to identify 
high risk individuals and histopathological approaches 
are used to determine ER, PR and HER2 expression, help-
ing to direct clinical intervention. Indeed, microarray-
based technologies for routine prognostic screening of 
multigene signatures (for example, 70-gene MammaPrint 
for tumour aggressiveness/chemotherapy requirement/
metastatic prognosis [48], Celera 14-gene for metastasis 
score [49], Oncotype-DX 21-gene signature for measur-
ing risk of re-occurrence [50], and 76-gene Veridex sig-
nature for tamoxifen therapy benefit [51]) have been 
invaluable in supporting treatment of ER/PR positive 
breast cancers. However, the identification of a specific 
biomarker for the detection of breast cancer at the ear-
liest stage that can be analysed in biopsies, has so far 
evaded the diagnostic industry. Proteins and metabolites 
have been discovered which were increased in malignant 
tissues compared to normal, but were subsequently found 
to be diluted beyond the level of detection in plasma or 
urine, or were found not to be specific for breast can-
cer. These have been reviewed extensively elsewhere 
and will not be covered here [52]. In addition, depletion 
methods may be required to remove the most abundant 
proteins such as albumins and immunoglobulins from 
plasma, prior to analysis, which can result in losses and 
further reduced sensitivity. It is therefore not surprising 
that a comprehensive review of breast cancer biomark-
ers in 2007 by the Update Committee of the American 
Society of Clinical Oncology failed to recommend any of 
the most promising candidates, including blood levels of 
CA 15-3 and CA 27.29 (both forms of mucin-1) for diag-
nosis, detection of recurrence, decisions on therapy or 
metastasis, or circulating truncated extracellular HER2 
for detection of breast cancer [53]. Clearly, accessing tis-
sue biopsies to look at tumour-associated biomarkers, 
where they are most concentrated, on a regular basis is 
not practical, though most of the accepted biomark-
ers ER, PR, HER2, urokinase-type plasminogen activa-
tor (uPA) and plasminogen activator inhibitor 1 (PAI-1) 
are currently analysed in tissues by immunohistochem-
istry or ELISA [53]. Hence, the challenge remains, how 
to provide a low cost, safe, simple, sensitive and specific 
method for detecting breast cancer, early enough, avoid 
unnecessary overtreatment and surgery? In this context, 
molecular diagnostic approaches for the early detection 
of breast cancer remain largely untapped.
Breast-specific liquid biopsies
By far the best liquid biopsies (or biofluids) for develop-
ing a screening diagnostic are those readily accessible and 
in close proximity to the disease area, such as saliva for 
oral cancers or urine for bladder or renal cancer (Table 2). 
In this respect, various methods have been developed to 
access ductal liquids that are associated with cells that are 
the origin of the majority of breast cancers. We present, 
a case for using nipple aspirate fluid (NAF) for routine 
breast cancer screening, but initially, review the various 
breast-associated fluids that have been studied, with a 
specific emphasis on proteomics characterisation.
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Milk and colostrum
There have been a number of proteomics studies on milk 
purely from a functional perspective, unrelated to can-
cer, with a recent study identifying up to 1600 proteins 
[54, 55]. Colostrum, produced 2 or 3 days prior to lacta-
tion, preparing the infants digestive system for milk as 
a food source and immunisation against infection, has 
also been characterised. In a study of 100 samples using 
2D liquid chromatography mass spectrometry (LC MS), 
151 proteins were identified after immunodepletion (to 
remove the most abundant proteins), including 83 found 
in colostrum but not milk [56]. Although available in use-
ful volumes for analysis, the period of production during 
the reproductive phase of life is relatively narrow and in 
most cases will not overlap with breast cancer develop-
ment. Consequently, there has been very little research 
on proteomic profiling of breast cancer in milk or colos-
trum because of the relatively small proportion of women 
in which the disease and postnatal breast-feeding, coin-
cide. Nevertheless, Schneider et  al. were able to profile 
samples from a small cohort and identified proteins that 
were uniquely present in milk from women diagnosed 
with breast cancer [57].
Breast cyst fluid
Several epidemiological and prospective studies indicate 
there may be a relationship between cystic breast disease 
and cancer [58]. There are two types of breast cyst (Type I 
or apocrine cysts and Type II) differentiated on the basis of 
morphological and cellular characteristics. Apocrine cysts 
differ from Type II cysts in having a higher  K+/Na+ ratios 
while Type I cysts are more strongly related with breast 
cancer [59]. According to Mannello et al., more than 100 
studies have identified 81 proteins in breast cyst fluid, with 
the major components identified as albumin, prolactin 
inducible protein, Zn-α2-glycoprotein, and apolipoprotein 
D [59]. A 2-D gel electrophoresis/mass spectrometry study 
on apocrine macrocyst fluid identified that 15-hydroxy-
prostaglandin dehydrogenase and 3-hydroxymethylglu-
taryl-CoA synthase were associated with cysts and tumour 
tissue and were absent in matched normal tissue [58].
Ductal lavage (DL)
Ductal lavage (DL) is a non-surgical breast epithelial 
sampling procedure that was developed to identify high 
risk breast cancer women and to detect malignant lesions 
in breast epithelial cells. In the DL procedure a micro-
catheter is cannulated to the ducts, infused by a saline 
solution, and then aspirated by a suction device to col-
lect cells from the lining of ducts. More cells are acquired 
through ductal lavage than from nipple aspiration [60], 
and liquid biopsies can be obtained from women that do 
not yield fluid by passive nipple aspiration or discharge or 
from breast massage. Ductal lavage containing sufficient 
cells was collected from 31 women (out of 36 volunteers) 
diagnosed with breast cancer and analysed for atypical 
cytology as a possible diagnostic indicator, however only 
13% produced a significant positive indication [61]. A 
separate study of 30 samples found that 23.3% of women 
had atypical lavage cytopathology; interestingly these 
women had normal mammogram screening of breast, 
indicating the potential for improved sensitivity [62]. 
The isolation of cells from ductal lavage opens up the 
opportunity for applying molecular biology approaches. 
Multiplex methylation-specific polymerase chain reac-
tion (QM-PCR) was used to quantitate cumulative gene 
promoter hypermethylation in multiple genes, which are 
markers for breast cancer, and found to double the sen-
sitivity of detection of cancer cells compared with cytol-
ogy [63]. An attempt to identify biomarkers of tamoxifen 
action (e.g. changes in expression of estrogen receptor α, 
Ki-67 and cyclooxygenase-2) in ductal lavage, however, 
found no significant cytological or molecular variations 
in patients [64]. Recently, an improved method of ductal 
aspiration, collecting multiple aliquots, considerably 
increased the cell recovery with 45/50 subjects yielding 
more than 1000 cells and 50% of those producing more 
than 20,000 cells with 80–100% epithelial cell purity. 
This provided genomic DNA, RNA and miRNA samples 
for analysis however, to date only qualitative observa-
tions of the molecular profiles have been reported [65]. 
Do Canto et al. identified more than 700 miRNAs from 
ductal lavage from women with unilateral breast can-
cer, of which 17 were differentially expressed between 
tumour and paired normal samples and have previously 
been associated with tumorigenic processes and signal-
ling pathways for invasiveness and metastases [66]. In a 
related study, the metabolomic profiles of ductal lavage of 
43 women with breast cancer was acquired [67]. From a 
total of 2098 compounds (detected in both positive and 
negative ion mode with a QTOF mass spectrometer), a 
signature of 21 metabolites (including N-acetyl-DL-tryp-
tophan, N-linoleoyl taurine, trans-2-dodecenoylcarnitine 
and specific phospholipid isoforms) was determined to 
provide a ROC Curve of 90.7% sensitivity in diagnosing 
breast cancer. However, ductal lavage can cause consider-
able discomfort which has prevented widespread clinical 
use [68]. Furthermore, the process of flushing the ducts, 
results in dilution of the protein components and hence 
reduced sensitivity for biomarker profiling.
Random Peri-areolar Fine Needle Aspiration 
(RPFNA)
RPFNA, developed by Dr. Carol Fabian in 1998, pro-
vides a snap-shot of the breast by sampling cells from the 
entire breast of asymptomatic women [69, 70]. The major 
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advantage of RPFNA is that it can be performed in the 
majority of women and the cell yields vary from 72 to 
85%, considerably higher than ductal lavage. [71]. After 
anesthetizing the breast with 1% lidocaine, five needle 
aspirations are made on the lateral breast site and four 
from the middle skin of each. The aspirated fluid consists 
of epithelial, immune, stromal and adipose cells [70].
A clinical trial of 480 women indicated that RPFNA 
increased detection of cytological atypia associated with 
breast cancer in high-risk women (based on family his-
tory, a prior diagnosis and precancerous biopsy) [70]. Of 
the cohort, 20 women subsequently developed breast 
cancer after 45 months (7 DCIS and 13 invasive), indicat-
ing a promising potential for very early diagnosis. RPFNA 
was used for a chemoprevention study of alpha-difluo-
romethylornithine (DFMO) in 119 high-risk women, 
but found no change in cytology or other RPFNA-based 
molecular markers such as expression of proliferating cell 
nuclear antigen, p53 or epidermal growth factor recep-
tor [72]. A proteomic microarray study found that up 
to 60 phosphoproteins can be verified in triplicate from 
5000 to 10,000 micro-dissected RPFNA epithelial cells, 
suggesting the possibility to track signalling pathways in 
order to understand the molecular changes occurring in 
mammary carcinogenesis [73]. The heterogeneous nature 
of the cell populations being tested for specific molecu-
lar markers and considerable discomfort to obtain the 
samples, are key limitations of the RPFNA approach. 
Furthermore, the difficulty in reproducing the method 
may preclude a role in screening of high-risk women that 
involves repeated harvesting of material.
Nipple aspirate fluid (NAF)
The breasts of adult non-lactating women secrete small 
volume of fluid, called “nipple aspirate fluid” (NAF, which 
here also includes spontaneous nipple discharge) into 
the breast ducts [74]. The research presented within this 
section relates to nipple secreted fluids collected by non-
invasive methods, either passive discharge or by use of 
massage or pumps, differentiating them from the invasive 
approaches previously described (ductal lavage RPFNA, 
etc.). There have been a series of seminal reviews outlin-
ing the importance of NAF for diagnosing breast cancer 
[75–78], however, the current review aims to promote the 
progression that has been achieved through the applica-
tion of ‘omics’ strategies. The fluid passes down the main 
ducts and ampullae through alveolar glands of breast, 
from which it enters the lymphatic and blood circulation 
[79]. Under normal conditions, the breast fluid cannot 
escape from the nipple because the ducts are blocked by 
viscous and dried-up secretions or because of the pres-
ence of constrictive bands of smooth muscle and kerati-
nized epithelium [79]. To maintain stable physiology of 
the breast, an equilibrium exists between fluid secretion 
and re-absorption. Several factors are associated with 
NAF production; age, ethnicity, early menarche, history 
of lactation, high dietary fat consumption and dietary 
intake of lactose [80]. There is also a direct relationship 
between ear wax and NAF because both are produced by 
modified apocrine glands (ceruminous and mammary, 
respectively). Women with wet ear wax yield more NAF, 
compared to women with dry ear wax [81]. Premenopau-
sal women with lactation experience, aged 30–50  years 
and who had early onset of menarche produce more 
NAF compared to those who have not had children [80]. 
A study of 25 to 49-year-old premenopausal nulliparous 
women found that proportionately, Asian-descendant 
women were less likely to produce NAF compared to 
White American women [53].
NAF collection has been achieved with varying degrees 
of success dependent on the method and the practitioner 
and, in some cases, has deterred researchers from further 
investigation. Electronic and manual breast pumps (nor-
mally used for lactation), massage, warming and combi-
nations of each have been used to acquire NAF samples 
[82]. Most promising has been the use of oxytocin nasal 
spray which helps the release of already existing fluid in 
the ducts increasing collection in 95% of patients and vol-
unteers [83].
NAF is a rich source of molecular and cellular infor-
mation. Indeed, in a composite study of published data 
on NAF cell content, cellularity or proliferative epithelial 
disease was observed to be an independent risk deter-
minant for breast cancer development [84]. This reflects 
the increased exfoliation of epithelial cells lining the 
ducts and lobules as they proliferate through hyperplasia, 
in  situ carcinoma and invasive carcinoma with disease 
progression [85]. The released cells not only increase in 
number but also change in appearance, exhibiting mor-
phological differences (irregularly shaped nuclei, rough 
endoplasmic cisternae and well-developed Golgi com-
plexes associated with nucleic acid and protein synthesis) 
[86].
NAF is also composed of a variety of endogenous sub-
stances such as lactose, proteins, fatty acids, hormones 
(estrogens, androgens, progesterone), sterols, but may 
also contain exogenous substances such as nicotine and 
cotinine from cigarette-smoking [74]. The colour of NAF 
varies from clear to brown, bloody, black, pale yellow, 
dark yellow, white or green [87], and is associated with 
the concentration of cholesterol, estradiol, estrone, cho-
lesterol epoxides and peroxidated lipids [88]. NAF has 
also been shown to contain microorganisms and the 
ductal microbiome was distinctly different from that of 
the nipple and areolar skin [89]. In addition, a compari-
son of 6 breast cancer patients (contralateral sample) 
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with 6 healthy controls (both breasts) showed varia-
tions in particular microbe genus incidence, indicating a 
potential role in the disease.
The colour of NAF is more an epidemiological factor 
than an indicator of the risk of breast cancer, however 
one study found that women have a higher risk of breast 
cancer with bloody or brown nipple discharge, compared 
to those which were white, cream, yellow or green [90]. 
Another study of 327 women found that the frequency 
of red or brown colour was increased with progression 
of disease from pre-cancer to cancer and surgical biopsy 
has more influence on NAF colour compared to needle 
biopsy [91].
NAF production, nutritional aspects and estrogen 
level have been found to be related to breast cancer risk. 
A large scale study of 1496 participants (1347 white and 
153 black women) found a positive association between 
higher dietary fat and NAF secretion in the group aged 
30–44 years [92]. As obesity is associated with a high fat 
diet and is a major risk factor for breast cancer, correla-
tion of fat intake, and NAF production and composition 
may be helpful for breast cancer prevention and progno-
sis [93]. A link between lactose and soy intake has also 
been reported, however contrary results from a rand-
omized crossover trial discovered no influence of soy 
on NAF volume and circulating estrogen level [94]. On 
the other hand, a fruit-and-vegetable diet was inversely 
related with NAF production while decreasing the circu-
lating hormone concentration [95]. The concentration of 
micro-nutrients, such as carotenoids and soy isoflavones 
in NAF, was also related to dietary intake [96].
NAF biomarkers
In order to place the ‘omics’ approaches to global analysis 
of molecular events in NAF profiling, into perspective, it 
is important to appraise the extensive research on spe-
cific biomarker targets that has been undertaken in NAF 
(Table 3). Based on the differential levels of testosterone 
in serum from pre- and postmenopausal women, Sauter 
et  al. measured testosterone levels in NAF samples and 
found it would be a suitable biomarker to predict breast 
cancer risk [97]. A separate study, which measured the 
level of free and albumin-bound testosterone in NAF, 
found high levels of the former in premenopausal women 
with breast cancer [98].
Thomsen–Friedenreich (TFr) and Tn antigens are 
aberrant O-linked mono- (GalNAc) or disaccharides 
(Gal-GalNAc) found on cell surface glycoproteins and 
associated with the progression of numerous cancers 
including bowel, skin, prostate and breast. A study of the 
expression of TFr and Tn antigens found that NAF of 
90% breast cancer patients have high content of TFr and 
Tn compared to normal NAF, because both antigens are 
present on the surface of epithelial cancer cells and lipids 
[99]. A recent study of 137 women found that the con-
centrations of TFr and Tn antigens were lower in women 
with benign disease, compared to those with atypical 
hyperplasia. They also found that the expression of TFr 
is more predictive for the presence of breast cancer or 
atypia compared to Tn [100].
Proteins are major constituents of NAF with concen-
trations that can be higher than plasma, up to 170  mg/
ml. NAF, most importantly, is enriched for proteins origi-
nating from epithelial cells lining the duct [101], some 
of which have been evaluated as potential biomarkers of 
breast cancer. Prostate specific antigen (PSA), also known 
as kallikrein-3 (KLK3), first identified in seminal plasma 
and prostatic tissue, produced by the epithelial cells lin-
ing the acini and ducts of prostate gland, has also been 
identified in female breast tumours [102]. A study of NAF 
found that women with no risk factors or family history 
of breast cancer had high levels of PSA, but women with 
precancerous or invasive cancer had reduced levels [103]. 
Furthermore, PSA levels were inversely proportional not 
only to disease stage, but also tumour size, node status 
and distant metastases [104].
The concentration of superoxide dismutase [Cu–Zn] 
(SOD-1) in NAF was decreased in breast cancer patients 
compared to healthy individuals [105]. SOD-1 is involved 
in cancer initiation and progression caused by reactive 
Table 3 A summary of putative biomarkers and their bio-
logical function that have been identified in nipple aspi-
rate fluid
Biomarker (s) Characteristics References
Prostate specific antigen 
(PSA)
Inversely proportional to 
disease stage, size of tumour, 
node status and distant 
metastases
[102–104]
Thomsen–Friedenreich 
(TFr) and Tn antigens
Predictive for the presence of 
breast cancer or atypia
[99, 100]
Testosterone Predictive in postmenopausal 
women only
[97, 98]
Superoxide dismutase 
(SOD‑1)
Involved in cancer initiation 
and progression by ROS 
related damages
[105]
Protein DJ‑1 mRNA level increased but pro‑
tein level decreased in tissue
[106]
Cytokines/chemokines High level of pro‑inflammatory 
C–C and CXC chemokines.
[107]
Plasminogen activator 
inhibitor‑1 (PAI‑1), 
urokinase‑type plasmi‑
nogen activator (uPA)
Promotes breast cancer inva‑
sion and metastasis
[110, 111]
Serotransferrin protein 
(TF) and ferritin (FTN)
Proliferation of cancer cells [109]
C‑reactive protein (CRP) Serum biomarker for metastasis 
of different type of cancers
[112, 113]
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oxygen species-related damage. Therefore, it was pro-
posed that measuring the concentration of SOD-1, a key 
antioxidant enzyme in breast microenvironment, may be 
helpful to differentiate between the normal and tumour 
breast.
The expression of anti-oxidant oncogene DJ-1 mRNA 
is increased in ductal carcinoma tissues but the opposite 
effect was observed at the protein level, where expres-
sion is decreased and contrarily was elevated in blood of 
breast cancer patients. A study on NAF collected from 
136 patients identified high levels of DJ-1 protein in NAF 
from breast cancer patients, but low levels in benign pap-
illoma cases [106].
NAF samples collected from non-cancer and can-
cer women for cytokine profiling found no differ-
ence in anti-inflammatory cytokines (IL-4, IL-9, IL-10 
and IL-13), pro-inflammatory cytokines (IL-2 and 
interferon-γ), immuno-modulatory interleukins (IL-5, 
IL-7) or chemokines (RANTES, IP-10, eotaxin). How-
ever, NAFs from cancer patients with high levels of alu-
minium in the breast microenvironment, had higher 
concentrations of pro-inflammatory cytokines (IL-1β, 
IL-6, IL-12 p70, and TNF-α), and C–C (MCP-1 and 
MIP-1α) and CXC-type chemokines (IL-8) compared 
to those cancer patients with low aluminium levels. 
This indicated a significant correlation between pro-
inflammatory cytokines (IL-6), monocyte/macrophage 
chemo-attractant chemokines (MIP-1α and MCP-1), 
oxidative stress and aluminium content in cancerous 
NAFs [107].
Cancer cells contain high levels of transferrin (TF) 
and ferritin (FTN), as well as higher expression of TF 
receptors compared to normal cells, suggesting proteins 
involved in Fe metabolism play important role in the 
proliferation of breast cancer cells [108]. A study of NAF 
collected from 66 women found that cancer patients 
(particularly postmenopausal) have high levels of TF and 
FTN, compared to healthy women [109]. Hence, measur-
ing soluble FTN and TF in NAF may help the early iden-
tification of women with increased breast cancer risk, 
even though these proteins are not expressed by local 
breast tissues.
Plasminogen activator inhibitor-1 (PAI-1), normally 
found in plasma, promotes breast cancer invasion and 
metastasis by directly inhibiting proteases, suggesting 
that excessive plasmin proteolysis may inhibit the assem-
bly of tumour blood vessels, modulation of cell adhesion 
and the stimulation of cell proliferation [110]. Signifi-
cantly higher levels of uPA and PAI-1, along with the 
Thomsen–Friedenreich antigen, have been reported in 
NAF of women with cancer, with the former more pre-
dictive for postmenopausal and the latter more indicative 
for premenopausal patients [111].
C-reactive protein (CRP) is already a developed serum 
biomarker for metastasis of various cancers including 
advanced stages of breast cancer [112]. Elevated CRP 
levels in ductal epithelia of the breast are an indicator of 
inflammatory processes associated with an early benign 
stage. A study on 59 samples found that CRP in NAF was 
positively related to the Gail model for breast cancer risk 
[113].
NAF proteomics
Proteomics approaches for characterising NAF has pre-
viously been reviewed by Mannello et  al. [114], since 
which there has been rapid advancement in mass spec-
trometric technology and the development of new 
quantitative strategies. On the basis of the unique char-
acteristics of NAF, proteomic analysis should serve as a 
useful approach to understand the physiology of breast 
cancer and for biomarker discovery. However, early prot-
eomic profiling of NAF samples collected from cancerous 
and non-cancerous breasts of patients using surface-
enhanced laser desorption ionization mass spectrometry 
(SELDI-MS), revealed no significant differences in the 
SELDI-MS peak profiles [115]. Use of more powerful sep-
aration techniques started to reveal differences. Varnum 
et  al. identified 64 proteins in immune-depleted NAF 
samples, using an ion trap mass spectrometer, among 
which 15 had previously been reported to be altered in 
tumour tissue and serum from women with breast can-
cer, including osteopontin and cathepsin D [116]. Two-
dimensional PAGE separation of proteins, followed by 
in-gel digestion with trypsin and matrix-assisted laser 
desorption ionization time-of-flight mass spectrometer 
(MALDI-TOF) analysis, identified 41 components in 
NAF [117]. Among these, levels of prolactin-inducible 
protein, apolipoprotein D, and α1-acid glycoprotein, were 
observed to be changed in cancer NAF samples. Further 
validation by ELISA, indicated that expression of these 
proteins correlated with pre-/postmenopausal status 
and cancer stage. Pawlik et al. [118] used Isotope-coded 
affinity tag (ICAT) tandem mass spectrometry (MS) for 
qualitative and quantitative analysis of tumour specific 
proteins in NAF, identified 353 peptides from 39 pro-
teins in NAF samples from 18 women with breast can-
cer and 4 healthy volunteers. Alpha-2-HS-glyoprotein, 
was found to be decreased, whereas lipophilin B, beta-
globin, hemopexin and vitamin-D binding protein were 
increased in breast cancer NAF samples. A recent study 
on six NAF samples (3 healthy individuals and 3 cancer 
patients) analysed by using an LTQ-Orbitrap XL mass 
spectrometer, identified more than 854 unique proteins, 
including established putative breast cancer biomark-
ers candidates, cancer antigen 15.3, tissue plasmino-
gen activator, uPA, and cathepsin D [119]. Recently, in 
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a series of experiments to optimise protein separation 
from a NAF sample, Brunoro et al. identified 557 differ-
ent proteins [120]. The most complete proteomics study 
was performed by Shaheed et al. [121], identifying more 
than 1900 unique gene products including mitogenic 
growth factors (IGF1, IGF2, EGF, PDGFC, PGGFD, 
TGFβ1, VEGFA), cell adhesion proteins (CEACAMs, 
NCAM2, ICAM1), established breast cancer biomarkers 
(EGFR, mucin-1/CA 15-3, mucin-16/CA-125, MUCL1, 
cytokeratins 5, 8, 14 and 18) as well as 46 candidate bio-
markers under investigation by the National Cancer 
Institute Early Detection Research Network [122]. A 
comparison of matched NAF pairs, from a healthy vol-
unteer and patients with benign, DCIS or invasive car-
cinoma, detected an average of more than 1200 proteins 
per sample [121]. While matched pairs exhibited strong 
similarity in profile, individuals showed significant dif-
ferences, confirming the observations by Brunoro et  al., 
using SDS PAGE and 2D-DIGE analysis of NAF [123]. 
Indeed, the composition of the healthy volunteer samples 
were disproportionately high in milk proteins, despite 
the fact that the subject had never breast fed. In this case, 
milk proteins were diagnostic for galactorrhea caused by 
prescribed medication inducing a nipple discharge [121]. 
The different protein profiles identified in NAF samples, 
collected by different groups, clearly highlight the poten-
tial for identifying biomarkers that could be related to the 
early development of breast cancer.
Conclusions
One of the major causes of death among women through-
out the world is breast cancer. Despite tremendous 
progress in understanding the causes and advances in 
treatment regimens, the options for women at high risk 
of breast cancer are limited to drastic surgical interven-
tion, because current methods for regular screening have 
significant limitations. Identifying biomarkers indicative 
of the earliest stages of malignancy has great potential, 
but so far it has not been fully explored. Cancer associ-
ated tissues are not readily accessible on a regular basis 
and plasma dilutes biomarkers once released from the 
diseased area. There would be huge benefits in analysing 
a biofluid collected from healthy volunteers and breast 
cancer patients that directly originates from the affected 
organ source. In this respect, NAF-based biomarkers 
offer great potential for developing an innovative non-
invasive, patient-led screening strategy. NAF has multiple 
advantages as a liquid biopsy for detection of breast can-
cer: (1) premenopausal women, for whom current diag-
nostic modalities are limiting, are more likely to produce 
NAF than postmenopausal women where ductal atrophy 
is prevalent, (2) NAF production is non-invasive and 
causes less discomfort compared to other breast cancer 
screening procedures [124–126], (3) obtaining matched 
pairs of samples provides an “internal” control for com-
paring disease with healthy, (4) NAF is produced in close 
proximity to the cells lining the ducts, which are associ-
ated with 85% of all breast malignancies, and as a con-
sequence is symptomatic of breast health, (5) biomarkers 
remain highly concentrated for analysis (compared to 
blood and urine where massive dilution significantly 
reduce detection sensitivity for tissue-derived proteins), 
and (6) sample preparation is reduced compared to tis-
sues, which require yield-reducing protein extraction 
steps. NAF volumes are small, but protein concentra-
tions are very high and are more than adequate for rep-
licate analyses with state-of-the-art mass spectrometric 
techniques.
In a study of matched pairs of NAF samples by multi-
ple reaction monitoring mass spectrometry (MRM MS), 
significant differences in prolactin inducible protein were 
observed between the diseased breast and the contralat-
eral healthy breast (Fig. 1). With an MRM MS approach 
there is the potential to develop a multiplexed assay that 
measures a number of markers of breast health, defin-
ing patient-specific composition, that can be monitored 
in a longitudinal study. A wider study of a panel of bio-
markers will provide increased specificity and would 
enable development of a clinical assay. This would pro-
vide high-risk women with a safe, convenient breast can-
cer detection program, which could be applied regularly 
to breast health surveillance, detect the earliest stages of 
the disease and avoid extreme preventative intervention 
procedures, such as elective bilateral mastectomy. Ulti-
mately, detection of biomarkers in NAF could represent 
a paradigm shift in breast cancer management empow-
ering women to express samples at home on a monthly 
or quarterly basis and analyse their own samples with a 
diagnostic kit, massively reducing the burden on health 
services (Fig. 2).
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